Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G B Grindey

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Anticancer Research|July 1, 1995
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmanninR M Schultz, R L Merriman, S L Andis, et al.
Chemical Research in Toxicology|September 1, 1992
Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureasW J Ehlhardt, J M Woodland, J F Worzalla, et al.
Cancer Research|February 15, 1994
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumorsL L Habeck, T A Leitner, K A Shackelford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1996
Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expressionS B Gates, L G Mendelsohn, K A Shackelford, et al.
Journal of Pharmaceutical Sciences|July 1, 1993
Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogsW J Ehlhardt, H R Sullivan, P G Wood, et al.
Investigational New Drugs|January 1, 1996
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft modelsR L Merriman, L W Hertel, R M Schultz, et al.
Journal of the National Cancer Institute|December 2, 1992
Antitumor activity and clinical pharmacology of sulofenur in ovarian cancerC W Taylor, D S Alberts, Y M Peng, et al.
Anti-Cancer Drugs|April 1, 1994
Phase I trial of sulofenur (LY186641) given orally on a daily x 21 scheduleT D Brown, T J O'Rourke, J G Kuhn, et al.
Seminars in Oncology|August 1, 1995
Medicinal chemistry of difluoropurinesS L Andis, J R Bewley, G B Boder, et al.
Oncology Research|January 1, 1993
Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenograftsR M Schultz, R L Merriman, J E Toth, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Anticancer Research|July 1, 1995
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmanninR M Schultz, R L Merriman, S L Andis, et al.
Chemical Research in Toxicology|September 1, 1992
Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureasW J Ehlhardt, J M Woodland, J F Worzalla, et al.
Cancer Research|February 15, 1994
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumorsL L Habeck, T A Leitner, K A Shackelford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1996
Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expressionS B Gates, L G Mendelsohn, K A Shackelford, et al.
Journal of Pharmaceutical Sciences|July 1, 1993
Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogsW J Ehlhardt, H R Sullivan, P G Wood, et al.
Investigational New Drugs|January 1, 1996
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft modelsR L Merriman, L W Hertel, R M Schultz, et al.
Journal of the National Cancer Institute|December 2, 1992
Antitumor activity and clinical pharmacology of sulofenur in ovarian cancerC W Taylor, D S Alberts, Y M Peng, et al.
Anti-Cancer Drugs|April 1, 1994
Phase I trial of sulofenur (LY186641) given orally on a daily x 21 scheduleT D Brown, T J O'Rourke, J G Kuhn, et al.
Seminars in Oncology|August 1, 1995
Medicinal chemistry of difluoropurinesS L Andis, J R Bewley, G B Boder, et al.
Oncology Research|January 1, 1993
Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenograftsR M Schultz, R L Merriman, J E Toth, et al.
Pageof 6